These results suggested that the transfer of IL-2-activated NK cells from the perfusion fluid of deceased donor liver transplantation could be a novel treatment for hepatocellular carcinoma via the pathway of up-regulating the expression of TRAIL. The gene discussed is IL2; the disease is hepatocellular carcinoma.